Texas Kazano LawyerThe diabetes drug Kazano is under FDA investigation for the risk of heart failure, pancreatic cancer, rhabdomyolysis, and other severe side effects.

Do I Have a Texas Kazano Lawsuit? Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged. If you or a loved one was diagnosed with a severe side effect, you should contact our lawyers immediately. You may be entitled to compensation by filing a lawsuit.

Kazano Side Effects

FDA Evaluating Rhabdomyolysis Risk

The FDA is evaluating a potential signals of a serious risk and new safety information linking DPP4 diabetes drugs and rhabdomyolysis. This potentially life-threatening kidney side effect was identified by the FDA Adverse Event Reporting System (FAERS) between April and June 2017.

Kazano and Heart Failure

April 5, 2016 — The FDA has issued a Safety Communication to warn that Kazano may increase the risk of heart failure, particularly in patients with pre-existing kidney disease or coronary heart disease. The label on Kazano has been updated to include the following warning:

“In the EXAMINE trial which enrolled patients with type 2 diabetes and recent acute coronary syndrome, 106 (3.9%) of patients treated with alogliptin and 89 (3.3%) of patients treated with placebo were hospitalized for congestive heart failure.”

Other FDA Safety Warnings for Kazano

August 28, 2015 The FDA has issued a Safety Communication about the risk of severe, disabling joint pain from Kazano. The warning was issued after the FDA reviewed its database of adverse events and found 33 reports of joint pain associated with DPP-4 inhibitors.  Click here to read more.

March 13, 2013 FDA Safety Alert for possible increased risk of pancreatitis and pre-cancerous cellular changes in the pancreas that may be a symptom of pancreatic cancer. Click here to read more.

What is Kazano?

Kazano (alogliptin and metformin) is a twice-daily oral medication that is used along with diet and exercise to improve glycemic control (blood-sugar levels) in adults with type-2 diabetes. It is manufactured by Takeda Pharmaceuticals and was approved by the FDA in January 2013.

Although metformin has a long history of treating diabetes, the alogliptin in Kazano is a new drug in the incretin mimetic class of anti-diabetes medications. It inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down digestive hormones known as incretin hormones. Kazano increases incretin levels, which causes insulin to be released from the pancreas. Kazano also reduces glucose (sugar) production by the liver.

What is the problem with Kazano?

Drugs in the incretin mimetic class have only been on the market since 2006, which means that they may have unanticipated long-term side effects. Kazano has been linked to post-marketing reports of pancreatitis (pancreas inflammation), which increases a patient’s risk of pancreatic cancer. There are also studies suggesting that incretin mimetic drugs may increase the risk of cancer. The problem with Kazano is that patients may be unaware of these potential side effects.

Study of Kazano and Pancreatic Cancer

Diabetes published a study in March 2013 authored by researchers who performed autopsies on pancreases that were taken from patients who had been using incretin mimetic drugs.

The researchers found that the pancreases were 40% more massive than normal pancreases, due to extreme proliferation of beta-cells. Many of these cells were abnormal, and some were pre-cancerous. Several patients had small pancreatic tumors called adenomas, which are benign but can become malignant. The researchers also warned about the increased risk of pancreatic surgery:

“Since the standard of care of a pancreatic neuroendocrine tumor, because of the risk of conversion to malignancy, even if benign, is surgical resection [i.e. removal], patients exposed to incretin therapy would seem to be at increased risk of requiring pancreatic surgery.”

Kazano Class Action Lawyer

The Clark Firm, LLP is nationally recognized as a class action law firm in Texas, but our trial lawyers are not filing a Kazano class action. Instead, we are filing individual lawsuits on behalf of people who were diagnosed with pancreatic cancer. Federal judges have consolidated over 750 individual lawsuits involving diabetes drugs in the incretin mimetic class. The Multi-District Litigation (MDL No. 2452) is located in the U.S. District Court for the Southern District of California.

Do I have a Kazano Lawsuit in Texas?

Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.

Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”

The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $260 million in verdicts and/or settlements. Please use the form below to contact us for a free Texas Kazano lawsuit review.